English
简体中文
Total: £ 56.28
Published Date: 2025-10-08 | Pages: 144 | Tables: 139 | Medical Care
The global Small Molecule Drug Conjugates (SMDCs) market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Small Molecule Drug Conjugates (SMDCs) are a class of drugs that combine small molecule drugs with other biologically active molecules by chemical means. This combination can improve the targeting of drugs, enhance their efficacy, and reduce systemic toxicity.
From a downstream perspective, Cancer accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Small Molecule Drug Conjugates (SMDCs) leading manufacturers including SciClone, Tarveda Therapeutics, Yafei (Shanghai) Biomedical Technology (Affinity), Vincerx Pharma, Novartis(Endocyte), Ascentawits Pharmaceuticals, Conway, Daiichi Sankyo, Bristol Myers Squibb, Cidara Therapeutics, etc., dominate supply; the top five capture approximately % of global revenue, with SciClone leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Small Molecule Drug Conjugates (SMDCs) market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
SciClone
Tarveda Therapeutics
Yafei (Shanghai) Biomedical Technology (Affinity)
Vincerx Pharma
Novartis(Endocyte)
Ascentawits Pharmaceuticals
Conway
Daiichi Sankyo
Bristol Myers Squibb
Cidara Therapeutics
Coherent Biopharma Suzhou Co
Segment by Type
PSMA
FOLR1
FAP
Other
Segment by Application
Cancer
Urogenital Diseases
Digestive Diseases
Skin and Musculoskeletal Diseases
Endocrine and Metabolic Diseases
Respiratory Diseases
Other
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Small Molecule Drug Conjugates (SMDCs) study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Small Molecule Drug Conjugates (SMDCs): Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Small Molecule Drug Conjugates (SMDCs) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 PSMA
1.2.3 FOLR1
1.2.4 FAP
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global Small Molecule Drug Conjugates (SMDCs) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Urogenital Diseases
1.3.4 Digestive Diseases
1.3.5 Skin and Musculoskeletal Diseases
1.3.6 Endocrine and Metabolic Diseases
1.3.7 Respiratory Diseases
1.3.8 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Small Molecule Drug Conjugates (SMDCs) Revenue Estimates and Forecasts 2020-2031
2.2 Global Small Molecule Drug Conjugates (SMDCs) Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Small Molecule Drug Conjugates (SMDCs) Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Small Molecule Drug Conjugates (SMDCs) Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 PSMA Market Size by Players
3.3.2 FOLR1 Market Size by Players
3.3.3 FAP Market Size by Players
3.3.4 Other Market Size by Players
3.4 Global Small Molecule Drug Conjugates (SMDCs) Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Small Molecule Drug Conjugates (SMDCs) Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Small Molecule Drug Conjugates (SMDCs) Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Small Molecule Drug Conjugates (SMDCs) Market Size by Type (2020-2031)
6.4 North America Small Molecule Drug Conjugates (SMDCs) Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Small Molecule Drug Conjugates (SMDCs) Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Small Molecule Drug Conjugates (SMDCs) Market Size by Type (2020-2031)
7.4 Europe Small Molecule Drug Conjugates (SMDCs) Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Small Molecule Drug Conjugates (SMDCs) Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Small Molecule Drug Conjugates (SMDCs) Market Size by Type (2020-2031)
8.4 Asia-Pacific Small Molecule Drug Conjugates (SMDCs) Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Small Molecule Drug Conjugates (SMDCs) Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Small Molecule Drug Conjugates (SMDCs) Market Size by Type (2020-2031)
9.4 Central and South America Small Molecule Drug Conjugates (SMDCs) Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Small Molecule Drug Conjugates (SMDCs) Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Small Molecule Drug Conjugates (SMDCs) Market Size by Type (2020-2031)
10.4 Middle East and Africa Small Molecule Drug Conjugates (SMDCs) Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Small Molecule Drug Conjugates (SMDCs) Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 SciClone
11.1.1 SciClone Corporation Information
11.1.2 SciClone Business Overview
11.1.3 SciClone Small Molecule Drug Conjugates (SMDCs) Product Features and Attributes
11.1.4 SciClone Small Molecule Drug Conjugates (SMDCs) Revenue and Gross Margin (2020-2025)
11.1.5 SciClone Small Molecule Drug Conjugates (SMDCs) Revenue by Product in 2024
11.1.6 SciClone Small Molecule Drug Conjugates (SMDCs) Revenue by Application in 2024
11.1.7 SciClone Small Molecule Drug Conjugates (SMDCs) Revenue by Geographic Area in 2024
11.1.8 SciClone Small Molecule Drug Conjugates (SMDCs) SWOT Analysis
11.1.9 SciClone Recent Developments
11.2 Tarveda Therapeutics
11.2.1 Tarveda Therapeutics Corporation Information
11.2.2 Tarveda Therapeutics Business Overview
11.2.3 Tarveda Therapeutics Small Molecule Drug Conjugates (SMDCs) Product Features and Attributes
11.2.4 Tarveda Therapeutics Small Molecule Drug Conjugates (SMDCs) Revenue and Gross Margin (2020-2025)
11.2.5 Tarveda Therapeutics Small Molecule Drug Conjugates (SMDCs) Revenue by Product in 2024
11.2.6 Tarveda Therapeutics Small Molecule Drug Conjugates (SMDCs) Revenue by Application in 2024
11.2.7 Tarveda Therapeutics Small Molecule Drug Conjugates (SMDCs) Revenue by Geographic Area in 2024
11.2.8 Tarveda Therapeutics Small Molecule Drug Conjugates (SMDCs) SWOT Analysis
11.2.9 Tarveda Therapeutics Recent Developments
11.3 Yafei (Shanghai) Biomedical Technology (Affinity)
11.3.1 Yafei (Shanghai) Biomedical Technology (Affinity) Corporation Information
11.3.2 Yafei (Shanghai) Biomedical Technology (Affinity) Business Overview
11.3.3 Yafei (Shanghai) Biomedical Technology (Affinity) Small Molecule Drug Conjugates (SMDCs) Product Features and Attributes
11.3.4 Yafei (Shanghai) Biomedical Technology (Affinity) Small Molecule Drug Conjugates (SMDCs) Revenue and Gross Margin (2020-2025)
11.3.5 Yafei (Shanghai) Biomedical Technology (Affinity) Small Molecule Drug Conjugates (SMDCs) Revenue by Product in 2024
11.3.6 Yafei (Shanghai) Biomedical Technology (Affinity) Small Molecule Drug Conjugates (SMDCs) Revenue by Application in 2024
11.3.7 Yafei (Shanghai) Biomedical Technology (Affinity) Small Molecule Drug Conjugates (SMDCs) Revenue by Geographic Area in 2024
11.3.8 Yafei (Shanghai) Biomedical Technology (Affinity) Small Molecule Drug Conjugates (SMDCs) SWOT Analysis
11.3.9 Yafei (Shanghai) Biomedical Technology (Affinity) Recent Developments
11.4 Vincerx Pharma
11.4.1 Vincerx Pharma Corporation Information
11.4.2 Vincerx Pharma Business Overview
11.4.3 Vincerx Pharma Small Molecule Drug Conjugates (SMDCs) Product Features and Attributes
11.4.4 Vincerx Pharma Small Molecule Drug Conjugates (SMDCs) Revenue and Gross Margin (2020-2025)
11.4.5 Vincerx Pharma Small Molecule Drug Conjugates (SMDCs) Revenue by Product in 2024
11.4.6 Vincerx Pharma Small Molecule Drug Conjugates (SMDCs) Revenue by Application in 2024
11.4.7 Vincerx Pharma Small Molecule Drug Conjugates (SMDCs) Revenue by Geographic Area in 2024
11.4.8 Vincerx Pharma Small Molecule Drug Conjugates (SMDCs) SWOT Analysis
11.4.9 Vincerx Pharma Recent Developments
11.5 Novartis(Endocyte)
11.5.1 Novartis(Endocyte) Corporation Information
11.5.2 Novartis(Endocyte) Business Overview
11.5.3 Novartis(Endocyte) Small Molecule Drug Conjugates (SMDCs) Product Features and Attributes
11.5.4 Novartis(Endocyte) Small Molecule Drug Conjugates (SMDCs) Revenue and Gross Margin (2020-2025)
11.5.5 Novartis(Endocyte) Small Molecule Drug Conjugates (SMDCs) Revenue by Product in 2024
11.5.6 Novartis(Endocyte) Small Molecule Drug Conjugates (SMDCs) Revenue by Application in 2024
11.5.7 Novartis(Endocyte) Small Molecule Drug Conjugates (SMDCs) Revenue by Geographic Area in 2024
11.5.8 Novartis(Endocyte) Small Molecule Drug Conjugates (SMDCs) SWOT Analysis
11.5.9 Novartis(Endocyte) Recent Developments
11.6 Ascentawits Pharmaceuticals
11.6.1 Ascentawits Pharmaceuticals Corporation Information
11.6.2 Ascentawits Pharmaceuticals Business Overview
11.6.3 Ascentawits Pharmaceuticals Small Molecule Drug Conjugates (SMDCs) Product Features and Attributes
11.6.4 Ascentawits Pharmaceuticals Small Molecule Drug Conjugates (SMDCs) Revenue and Gross Margin (2020-2025)
11.6.5 Ascentawits Pharmaceuticals Recent Developments
11.7 Conway
11.7.1 Conway Corporation Information
11.7.2 Conway Business Overview
11.7.3 Conway Small Molecule Drug Conjugates (SMDCs) Product Features and Attributes
11.7.4 Conway Small Molecule Drug Conjugates (SMDCs) Revenue and Gross Margin (2020-2025)
11.7.5 Conway Recent Developments
11.8 Daiichi Sankyo
11.8.1 Daiichi Sankyo Corporation Information
11.8.2 Daiichi Sankyo Business Overview
11.8.3 Daiichi Sankyo Small Molecule Drug Conjugates (SMDCs) Product Features and Attributes
11.8.4 Daiichi Sankyo Small Molecule Drug Conjugates (SMDCs) Revenue and Gross Margin (2020-2025)
11.8.5 Daiichi Sankyo Recent Developments
11.9 Bristol Myers Squibb
11.9.1 Bristol Myers Squibb Corporation Information
11.9.2 Bristol Myers Squibb Business Overview
11.9.3 Bristol Myers Squibb Small Molecule Drug Conjugates (SMDCs) Product Features and Attributes
11.9.4 Bristol Myers Squibb Small Molecule Drug Conjugates (SMDCs) Revenue and Gross Margin (2020-2025)
11.9.5 Bristol Myers Squibb Recent Developments
11.10 Cidara Therapeutics
11.10.1 Cidara Therapeutics Corporation Information
11.10.2 Cidara Therapeutics Business Overview
11.10.3 Cidara Therapeutics Small Molecule Drug Conjugates (SMDCs) Product Features and Attributes
11.10.4 Cidara Therapeutics Small Molecule Drug Conjugates (SMDCs) Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Coherent Biopharma Suzhou Co
11.11.1 Coherent Biopharma Suzhou Co Corporation Information
11.11.2 Coherent Biopharma Suzhou Co Business Overview
11.11.3 Coherent Biopharma Suzhou Co Small Molecule Drug Conjugates (SMDCs) Product Features and Attributes
11.11.4 Coherent Biopharma Suzhou Co Small Molecule Drug Conjugates (SMDCs) Revenue and Gross Margin (2020-2025)
11.11.5 Coherent Biopharma Suzhou Co Recent Developments
12 Small Molecule Drug Conjugates (SMDCs)Industry Chain Analysis
12.1 Small Molecule Drug Conjugates (SMDCs) Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Small Molecule Drug Conjugates (SMDCs) Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Small Molecule Drug Conjugates (SMDCs) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Small Molecule Drug Conjugates (SMDCs) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Small Molecule Drug Conjugates (SMDCs) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Small Molecule Drug Conjugates (SMDCs) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Small Molecule Drug Conjugates (SMDCs) Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Small Molecule Drug Conjugates (SMDCs) Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Small Molecule Drug Conjugates (SMDCs) Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Small Molecule Drug Conjugates (SMDCs) Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Small Molecule Drug Conjugates (SMDCs) by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Small Molecule Drug Conjugates (SMDCs) as of 2024)
Table 11. Global Small Molecule Drug Conjugates (SMDCs) Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Small Molecule Drug Conjugates (SMDCs) Companies Headquarters
Table 13. Global Small Molecule Drug Conjugates (SMDCs) Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Small Molecule Drug Conjugates (SMDCs) Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Small Molecule Drug Conjugates (SMDCs) Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Small Molecule Drug Conjugates (SMDCs) Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Small Molecule Drug Conjugates (SMDCs) Revenue by Application (2026-2031) & (US$ Million)
Table 21. Small Molecule Drug Conjugates (SMDCs) High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Small Molecule Drug Conjugates (SMDCs) Growth Accelerators and Market Barriers
Table 25. North America Small Molecule Drug Conjugates (SMDCs) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Small Molecule Drug Conjugates (SMDCs) Growth Accelerators and Market Barriers
Table 27. Europe Small Molecule Drug Conjugates (SMDCs) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Small Molecule Drug Conjugates (SMDCs) Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Small Molecule Drug Conjugates (SMDCs) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Small Molecule Drug Conjugates (SMDCs) Investment Opportunities and Key Challenges
Table 31. Central and South America Small Molecule Drug Conjugates (SMDCs) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Small Molecule Drug Conjugates (SMDCs) Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Small Molecule Drug Conjugates (SMDCs) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. SciClone Corporation Information
Table 35. SciClone Description and Major Businesses
Table 36. SciClone Product Features and Attributes
Table 37. SciClone Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. SciClone Revenue Proportion by Product in 2024
Table 39. SciClone Revenue Proportion by Application in 2024
Table 40. SciClone Revenue Proportion by Geographic Area in 2024
Table 41. SciClone Small Molecule Drug Conjugates (SMDCs) SWOT Analysis
Table 42. SciClone Recent Developments
Table 43. Tarveda Therapeutics Corporation Information
Table 44. Tarveda Therapeutics Description and Major Businesses
Table 45. Tarveda Therapeutics Product Features and Attributes
Table 46. Tarveda Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Tarveda Therapeutics Revenue Proportion by Product in 2024
Table 48. Tarveda Therapeutics Revenue Proportion by Application in 2024
Table 49. Tarveda Therapeutics Revenue Proportion by Geographic Area in 2024
Table 50. Tarveda Therapeutics Small Molecule Drug Conjugates (SMDCs) SWOT Analysis
Table 51. Tarveda Therapeutics Recent Developments
Table 52. Yafei (Shanghai) Biomedical Technology (Affinity) Corporation Information
Table 53. Yafei (Shanghai) Biomedical Technology (Affinity) Description and Major Businesses
Table 54. Yafei (Shanghai) Biomedical Technology (Affinity) Product Features and Attributes
Table 55. Yafei (Shanghai) Biomedical Technology (Affinity) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Yafei (Shanghai) Biomedical Technology (Affinity) Revenue Proportion by Product in 2024
Table 57. Yafei (Shanghai) Biomedical Technology (Affinity) Revenue Proportion by Application in 2024
Table 58. Yafei (Shanghai) Biomedical Technology (Affinity) Revenue Proportion by Geographic Area in 2024
Table 59. Yafei (Shanghai) Biomedical Technology (Affinity) Small Molecule Drug Conjugates (SMDCs) SWOT Analysis
Table 60. Yafei (Shanghai) Biomedical Technology (Affinity) Recent Developments
Table 61. Vincerx Pharma Corporation Information
Table 62. Vincerx Pharma Description and Major Businesses
Table 63. Vincerx Pharma Product Features and Attributes
Table 64. Vincerx Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Vincerx Pharma Revenue Proportion by Product in 2024
Table 66. Vincerx Pharma Revenue Proportion by Application in 2024
Table 67. Vincerx Pharma Revenue Proportion by Geographic Area in 2024
Table 68. Vincerx Pharma Small Molecule Drug Conjugates (SMDCs) SWOT Analysis
Table 69. Vincerx Pharma Recent Developments
Table 70. Novartis(Endocyte) Corporation Information
Table 71. Novartis(Endocyte) Description and Major Businesses
Table 72. Novartis(Endocyte) Product Features and Attributes
Table 73. Novartis(Endocyte) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Novartis(Endocyte) Revenue Proportion by Product in 2024
Table 75. Novartis(Endocyte) Revenue Proportion by Application in 2024
Table 76. Novartis(Endocyte) Revenue Proportion by Geographic Area in 2024
Table 77. Novartis(Endocyte) Small Molecule Drug Conjugates (SMDCs) SWOT Analysis
Table 78. Novartis(Endocyte) Recent Developments
Table 79. Ascentawits Pharmaceuticals Corporation Information
Table 80. Ascentawits Pharmaceuticals Description and Major Businesses
Table 81. Ascentawits Pharmaceuticals Product Features and Attributes
Table 82. Ascentawits Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Ascentawits Pharmaceuticals Recent Developments
Table 84. Conway Corporation Information
Table 85. Conway Description and Major Businesses
Table 86. Conway Product Features and Attributes
Table 87. Conway Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Conway Recent Developments
Table 89. Daiichi Sankyo Corporation Information
Table 90. Daiichi Sankyo Description and Major Businesses
Table 91. Daiichi Sankyo Product Features and Attributes
Table 92. Daiichi Sankyo Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Daiichi Sankyo Recent Developments
Table 94. Bristol Myers Squibb Corporation Information
Table 95. Bristol Myers Squibb Description and Major Businesses
Table 96. Bristol Myers Squibb Product Features and Attributes
Table 97. Bristol Myers Squibb Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Bristol Myers Squibb Recent Developments
Table 99. Cidara Therapeutics Corporation Information
Table 100. Cidara Therapeutics Description and Major Businesses
Table 101. Cidara Therapeutics Product Features and Attributes
Table 102. Cidara Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Cidara Therapeutics Recent Developments
Table 104. Coherent Biopharma Suzhou Co Corporation Information
Table 105. Coherent Biopharma Suzhou Co Description and Major Businesses
Table 106. Coherent Biopharma Suzhou Co Product Features and Attributes
Table 107. Coherent Biopharma Suzhou Co Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Coherent Biopharma Suzhou Co Recent Developments
Table 109. Raw Materials Key Suppliers
Table 110. Distributors List
Table 111. Market Trends and Market Evolution
Table 112. Market Drivers and Opportunities
Table 113. Market Challenges, Risks, and Restraints
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Small Molecule Drug Conjugates (SMDCs) Product Picture
Figure 2. Global Small Molecule Drug Conjugates (SMDCs) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. PSMA Product Picture
Figure 4. FOLR1 Product Picture
Figure 5. FAP Product Picture
Figure 6. Other Product Picture
Figure 7. Global Small Molecule Drug Conjugates (SMDCs) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Cancer
Figure 9. Urogenital Diseases
Figure 10. Digestive Diseases
Figure 11. Skin and Musculoskeletal Diseases
Figure 12. Endocrine and Metabolic Diseases
Figure 13. Respiratory Diseases
Figure 14. Other
Figure 15. Small Molecule Drug Conjugates (SMDCs) Report Years Considered
Figure 16. Global Small Molecule Drug Conjugates (SMDCs) Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 18. Global Small Molecule Drug Conjugates (SMDCs) Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 19. Global Small Molecule Drug Conjugates (SMDCs) Revenue Market Share by Region (2020-2031)
Figure 20. Global Small Molecule Drug Conjugates (SMDCs) Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. PSMA Revenue Market Share by Player in 2024
Figure 23. FOLR1 Revenue Market Share by Player in 2024
Figure 24. FAP Revenue Market Share by Player in 2024
Figure 25. Other Revenue Market Share by Player in 2024
Figure 26. Global Small Molecule Drug Conjugates (SMDCs) Revenue Market Share by Type (2020-2031)
Figure 27. Global Small Molecule Drug Conjugates (SMDCs) Revenue Market Share by Application (2020-2031)
Figure 28. North America Small Molecule Drug Conjugates (SMDCs) Revenue YoY (2020-2031) & (US$ Million)
Figure 29. North America Top 5 Players Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) in 2024
Figure 30. North America Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) by Application (2020-2031)
Figure 32. US Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 33. Canada Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 34. Mexico Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 35. Europe Small Molecule Drug Conjugates (SMDCs) Revenue YoY (2020-2031) & (US$ Million)
Figure 36. Europe Top 5 Players Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) in 2024
Figure 37. Europe Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) by Type (2020-2031)
Figure 38. Europe Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) by Application (2020-2031)
Figure 39. Germany Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 40. France Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 41. U.K. Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 42. Italy Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 43. Russia Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 44. Asia-Pacific Small Molecule Drug Conjugates (SMDCs) Revenue YoY (2020-2031) & (US$ Million)
Figure 45. Asia-Pacific Top 8 Players Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) in 2024
Figure 46. Asia-Pacific Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) by Type (2020-2031)
Figure 47. Asia-Pacific Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) by Application (2020-2031)
Figure 48. Indonesia Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 49. Japan Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 50. South Korea Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 51. Australia Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 52. India Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 53. Indonesia Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 54. Vietnam Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 55. Malaysia Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 56. Philippines Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 57. Singapore Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2031) & (US$ Million)
Figure 58. Central and South America Small Molecule Drug Conjugates (SMDCs) Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Central and South America Top 5 Players Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) in 2024
Figure 60. Central and South America Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) by Type (2020-2031)
Figure 61. Central and South America Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) by Application (2020-2031)
Figure 62. Brazil Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2025) & (US$ Million)
Figure 63. Argentina Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2025) & (US$ Million)
Figure 64. Middle East and Africa Small Molecule Drug Conjugates (SMDCs) Revenue YoY (2020-2031) & (US$ Million)
Figure 65. Middle East and Africa Top 5 Players Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) in 2024
Figure 66. South America Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) by Type (2020-2031)
Figure 67. Middle East and Africa Small Molecule Drug Conjugates (SMDCs) Revenue (US$ Million) by Application (2020-2031)
Figure 68. GCC Countries Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2025) & (US$ Million)
Figure 69. Israel Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2025) & (US$ Million)
Figure 70. Egypt Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2025) & (US$ Million)
Figure 71. South Africa Small Molecule Drug Conjugates (SMDCs) Revenue (2020-2025) & (US$ Million)
Figure 72. Small Molecule Drug Conjugates (SMDCs) Industry Chain Mapping
Figure 73. Channels of Distribution (Direct Vs Distribution)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
